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Pilot randomised controlled trial of Help4Mood, an embodied virtual agent based 
system to support treatment of depression.  
 
Christopher Burton, Aurora Szentagotai Tatar, Brian McKinstry, Colin Matheson, 
Silviu Matu, Ramona Moldovan, Michele Macnab, Elaine Farrow, Daniel David, 





Help4Mood is an interactive system with an embodied virtual agent (avatar) to assist 
in self-monitoring of patients receiving treatment for depression. Help4Mood 
supports self-report and biometric monitoring and includes elements of cognitive 
behavioural therapy. 
We aimed to evaluate system use and acceptability; explore likely recruitment and 
retention rates in a clinical trial  and obtain an estimate of potential treatment response 
with a view to conducting a future randomised controlled trial (RCT) 
Methods 
We conducted a pilot RCT of Help4Mood in three centres, in Romania, UK and 
Spain. Patients with diagnosed depression (Major Depressive Disorder) and current 
mild/moderate depressive symptoms were randomised to use the system for 4 weeks 
in addition to treatment as usual (TAU) or to TAU alone.  
Results 
Twenty-seven individuals were randomised and follow up data were obtained from 21 
participants (12/13 Help4Mood, 9/14 TAU). Half of participants randomised to 
Help4Mood used it regularly (more than 10 times); none used it every day. 
Acceptability varied between users. Some valued the emotional responsiveness of the 
system, while others found it too repetitive. Intention to treat analysis showed a small 
difference in change of BDI-2 scores (Help4Mood -5.7 points, TAU -4.2). Post-hoc 
on-treatment analysis suggested that participants who used Help4Mood regularly 
experienced a median change in BDI-2 of -8 points.   
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Conclusion: Help4Mood is acceptable to some patients receiving treatment for 
depression although none used it as regularly as intended. Changes in depression 







Depression is the most common mental disorder worldwide1 and affects at least 5% of 
the population in Europe.2 Its impact on quality of life and morbidity are similar to 
those of other chronic conditions such as rheumatoid arthritis and diabetes.3 Most 
people with mild or moderate forms of clinical depression (Major Depressive 
Disorder) are treated in the community with pharmacological or psychological 
therapies, often in primary care. They usually receive relatively infrequent contact 
with their treating clinician.   
 
Computer- or Internet- delivered Cognitive Behaviour Therapy (CCBT/ICBT) can 
increase patients’ access to psychological treatments for depression but requires 
additional clinician support (which can be provided face to face or via the telephone) 
in order to lower attrition rates4 and increase effectiveness5. Standard ICBT packages 
rely primarily on self-report and do not accommodate objective measures such as 
activity6 or speaking patterns7 that have been shown to correlate with depressive 
symptoms. 
 
Help4Mood is a novel computer application designed to support people undergoing 
treatment for depression between appointments with their clinician. It uses self-
monitoring of mood, thoughts, activity and speech to generate new information for 
both patient and clinician and encourages patients to reflect on common patterns of 
negative thinking using elements of CBT. Help4Mood was developed in an iterative 
process, including people with depression and clinicians treating depression8,9 It is 
designed to be used by patients who have been diagnosed with depression, have 
 5 
current depressive symptoms, are well enough to undertake regular self-monitoring, 
and are unlikely to require urgent crisis support.  
 
In Help4Mood, standard symptom self-report tools that include mood, sleep, 
thoughts, and behaviours are supplemented by accelerometer measurement of 
physical activity and acoustic analysis of speech. Patients interact with Help4Mood 
using a simple Graphical User Interface that features a Virtual Agent which talks 
users through exercises and activities and varies content of responses and facial 
expressions in response to user input. The main aim of the Virtual Agent was to 
promote user engagement and adherence. The user interface is shown in Figure 1.  
 
FIGURE 1 ABOUT HERE 
 
Help4Mood includes simple elements of cognitive behavioural treatments to guide 
self-reflection and provides regular summaries of progress for the patient and their 
supervising clinician, which are designed to provide a succinct overview of any 
changes in the patient’s conditions and can be discussed during consultations. 
 
We aimed to conduct a pilot randomised controlled trial of Help4Mood in order to (a) 
evaluate system use and acceptability in patients with depression; (b) examine likely 
recruitment and retention to a substantive clinical trial of Help4Mood; (c) obtain an 
estimate of potential treatment response for use in planning a formal efficacy trial.  
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METHODS 
We conducted a pilot randomised controlled trial with two parallel groups, 
Help4Mood (H4M) plus treatment as usual (TAU), and TAU only. The trial ran in 
three sites, one each in the UK, Romania, and Spain.  
Patients with major depression diagnosed by their treating clinician and who had 
current depressive symptoms were recruited to a trial in which they were allocated to 
one of the two groups. Full details of the trial sites and trial procedures for patient 
identification and enrolment are described in Supplementary File 1 . 
Relevant ethical approvals were obtained for each site. The study was registered with 
a clinical trials database (ISRCTN 87615455). 
Participant identification and enrolment  
Patients were invited in writing by clinicians in the three countries from their active 
caseloads and by identification through practice computer searches. As this study 
involved patients currently receiving treatment from their clinician we used the 
treating clinician’s diagnosis backed up by self-report measures of depressive 
symptoms rather than a formal psychiatric interview schedule. 
 Interested individuals were then seen in person to assess eligibility, and complete 
informed consent, if eligible. Following consent, participants completed baseline 
questionnaires, underwent randomisation and arranged an appointment to receive the 
Help4Mood intervention. 
Eligibility and exclusion criteria 
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Participants were eligible if they met all of the following criteria: age 18-64, clinical 
diagnosis of major depressive disorder; if taking anti-depressant medication, no 
change in the last four weeks. 
Participants were excluded if they met any of the following criteria: baseline Beck 
Depression Inventory II15 (BDI-2) below 10 or greater than 30; significant thoughts of 
self-harm or suicide; history of recent self-harm, substance abuse, bipolar disorder, 
psychosis or learning difficulty; currently receiving  specialist psychological therapy; 
on augmented antidepressant therapy;   
 
Randomisation and treatment allocation 
Randomisation was conducted by an independent statistician using a variable block 
design. Allocations were sent to independent coordinators at each site and then 
prepared in sealed opaque envelopes to be opened after completion of the informed 
consent process and baseline measures. Outcome measures were collected un-blinded 
to participant allocation but primary data analysis was conducted blind to allocation.  
Intervention package  
Help4Mood consists of three main components, a Personal Monitoring System 
(PMS), a Decision Support System (DSS), and a Virtual Agent Interface.10 
Monitoring within Help4Mood is conducted by completion of on-screen items, guided 
by the talking virtual agent. The PMS focuses on activity monitoring with an 
accelerometer, which users choose to either wear on the wrist or carry in a pocket.11 
The DSS plans user sessions to provide variety and ensure sufficient data on self-
reported symptoms is collected across a week12. The DSS generates short, medium 
and long sessions and the user selects their preferred session length each time they use 
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the system. A full list of components can be found in Table 1. The only component 
patients saw every day was the Daily Mood Check, which was based on the CES-D-
VAS-VA.13 
TABLE 1 ABOUT HERE 
The Virtual Agent is an animated human-based character whose gender, clothing style 
(formal/informal), voice, and language (English, Spanish or Romanian) are selectable 
during configuration for an individual. The Agent adapts speech content, delivery and 
facial expression in response to the user’s actions; reactions are determined using a 
flexible cognitive emotional model.14 
Help4Mood contains two safety components. First, there is a “crisis plan” with 
personalised contact numbers and distress management behaviours, which is available 
at any time through the user interface. Secondly, the patient’s overall depressive 
symptoms are assessed every week using the PHQ923. Should the PHQ9 deteriorate 
by two points or more compared to the previous score, or should the patient indicate 
more than occasional thoughts of self-harm, Help4Mood prompts the participant to 
consider contacting "a professional or other person", followed by the crisis plan. From 
that point on, only basic mood check data is collected; other system functions are 
unavailable.  
Help4Mood was provided on a standard laptop computer rather than online because 
of the processing demands of the DSS and the Virtual Agent. Access was via a 
password-protected account, and the computer software was limited to the minimum 
applications necessary to support the Help4Mood system. The computer was supplied 
with internet access to transmit encrypted progress reports from Help4Mood, but was 
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otherwise locked down, to ensure optimal protection of the confidential patient data 
generated.  
Use of Help4Mood 
Participants randomized to Help4Mood were requested to use the system every day in 
their own home. Because of the content of the system, they were advised to use it in 
personal time or a private space. They were also asked to schedule appointments with 
their usual clinician, either face to face or by phone, at two weeks and at four weeks 
to discuss any reports generated by the Help4Mood system.  
Treatment as Usual 
TAU was provided to both allocation groups and comprised regular (fortnightly) 
scheduled appointments, additional appointments if needed and continuation of 
existing treatment as per the relevant local health systems and practices.  
Follow up 
Participants randomised to Help4Mood were contacted by the researcher after 2 
weeks by telephone to check for any problems. All participants were invited to a 
follow up assessment four weeks after randomisation or beginning to use Help4Mood. 
Non-attenders received one further follow up telephone reminder.  
Outcomes 
Assessment of system use and acceptability 
The Help4Mood system recorded detailed logs of system use and these were retrieved 
at the end of each four week period of use. The number and duration of times that 
each component of Help4Mood was used, and all monitoring data were extracted. 
Participants allocated to Help4Mood were debriefed in a semi-structured interview 
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which explored their experience of using the system and their views on the individual 
components. Interviews were transcribed and analysed using thematic analysis.  
Measures relating to depression 
At baseline and four weeks participants completed the Beck Depression Inventory II 
(BDI-2)15; the Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR)16; 
Dysfunctional Attitude Scale - Short Form 217  (DAS-SF 2, a measure of common 
negative cognitions) and the EQ-5D-5L generic quality of life measure.18  
Sample Size and Statistical Analysis 
We aimed to recruit 52 participants, but owing to time constraints and lower than 
expected uptake by potential participants the study was closed after 28 participants 
were recruited.  
Analysis 
Questionnaire data were summarised using mean and standard deviation and plotted 
to examine individual changes. While this study was not powered to show statistically 
significant differences between allocation groups, we examined changes from 
baseline in BDI-2, QIDS-SR, EQ-5D-5L and DAS-SF2 in each group. Where data at 
follow up were missing we did not attempt to impute data. There were no pre-
specified subgroup analyses, however we conducted a post hoc comparison of 
changes in BDI-2 between participants randomised to Help4Mood who were high and 
low users, based on the number of sessions and total time spent using Help4Mood. 
RESULTS 
Participant identification, recruitment and retention 
 11 
In total 52 patients expressed an interest in taking part and following eligibility 
screening and explanation of the study 28 patients were randomised, 14 to 
Help4Mood and 14 to TAU. The CONSORT diagram for this study is shown in 
Figure 2. Owing to an administrative error one Spanish patient randomised to TAU 
was incorrectly given the Help4Mood system. The patient was allowed to continue 
using the system but their data were excluded from the analysis.  
FIGURE 2 ABOUT HERE 
Eleven of the 13 (85%) participants correctly allocated to Help4Mood completed 
follow up measures between 4 and 6 weeks after randomization. One was withdrawn, 
and completed follow up measures early, because a routine PHQ measure within 
Help4Mood returned a score which met the critical threshold of 2 or more points 
above baseline discussed above. Although this triggered an alert and study 
withdrawal, the participant had not perceived any worsening of mood.   Five (33%) 
participants allocated to TAU did not respond to invitations to complete follow up 
measures.  
Participant Characteristics  
Participant characteristics are shown in Table 2.  Help4Mood and TAU groups were 
comparable with regard to sex, education, age, and medication status.  
TABLE 2 ABOUT HERE 
Table 2 also contains baseline scores of depressive symptoms and other measures. 
The mean BDI-II score was 20.7 (SD 7.7). Based on the BDI-II score, depressive 
symptoms were mild (less than 20) in 14 (52%), moderate (20-28) in 6 (22%) and 
severe (29 or 30) in 7 (26%).  
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Acceptability of Intervention 
Data on the use of Help4Mood were available from 12 participants: equipment failure 
resulted in data loss from one participant. The median number of times that 
Help4Mood was used was 10.5 (twice a week or more) and the median total duration 
was 134 minutes. Two participants appeared to have used the system for only one or 
two days, three used it on 3—7 days (casual users), and six used Help4Mood at least 
twice a week (10 times or more, regular users). Details of the number and length of 
session are reported in supplementary file 1. 
Estimates of Potential Treatment Effects 
Table 3 shows the post treatment values, and differences from mean baseline values 
for the measures of depressive symptoms and cognitions and quality of life. The large 
change seen in EQ-5D-5L was accounted for by a marked spontaneous improvement 
in one participant allocated to TAU.  
TABLE 3 ABOUT HERE 
The BDI-2 scores of both groups improved. Since usage data for the Help4Mood 
system showed a clear distinction between regular and casual users, we also 
calculated the change in BDI-2 for each user group. Regular users showed a median 
reduction of 8 points as opposed to 3 points for casual users. A reduction in BDI-2 
from baseline of 5 or more points or 30% is regarded as representing a clinically 
important difference19.  
Participant Feedback 
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Since a detailed qualitative analysis of participant feedback is outside the scope of this 
paper, we focus on key themes that concern the two most innovative components, the 
embodied Virtual Agent and the DSS. Both were designed to maintain user 
engagement and address the tedium of answering the same questions each day.  
Almost all of our participants would use Help4Mood for themselves, once a final 
version had been developed, and would recommend it to other people with 
depression. 
 “I think it is a useful system. For me at least, it was very helpful in some 
moments when I felt low and I did those exercises. It gave me some energy. I 
hope you will improve it so that it can be more useful.” (RO12, female, 
Romania) 
 
Participants were divided in their response to the Agent, whose behaviour had been 
modelled on that of a friendly, but professional therapist. Overall, they liked the 
ability to customise gender and appearance. Some valued the Agent’s responsiveness 
and appeared to have established a relationship with it. For example, at the exit 
interview, participant RO10 said of her female Agent, “I will miss her.” Others, 
however, found their Agents too cold and repetitive.  
Participants also differed in the amount of realism they required of the Agent. While 
participant SCO01 criticized the Agent for not being sufficiently realistic, participant 
SCO06 requested less realism, and would have been happy with a cartoon animal.  
Most participants noticed clear differences between sessions of different lengths, and 
appreciated the opportunity to tailor session length to their needs. 
“I could choose the type of session I wanted… if one day I needed a long 
session, I could choose a long one. Sometimes, when I was not in a good mood 
I could choose a shorter version and I liked that.” (RO14) 
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Despite the variation provided by the DSS, participants grew tired of performing a 
similar set of tasks in every session. They requested a more customizable experience 
that allowed them direct access to the parts of Help4Mood they preferred and 
suggested additional content such as psychoeducation. 
 
DISCUSSION 
Help4Mood is the first computer-based system to support depression treatment that 
uses an onscreen embodied Virtual Agent to maintain user engagement. It was 
developed iteratively with potential users (patients and clinicians) and designed to 
complement existing care. While the overall results only indicate a small 
improvement in mean BDI-2 scores, regular users appeared to obtain a greater benefit 
than non-regular users and the effect seen in regular users was potentially meaningful. 
Acceptability, adherence and outcomes were broadly similar between the two larger 
sites in Scotland and Romania.  
Strengths and limitations 
Although a case study series involving an earlier prototype with almost full 
functionality suggested high acceptability of Help4Mood,20 in this trial, almost all 
participants found it inconvenient or inappropriate to use Help4Mood every day as 
intended.  
It appears that daily symptom tracking may be less attractive for this patient group 
than has been found for bipolar disorder, a condition characterised by susceptibility to 
both depressive and manic episodes.21  
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Another reason for irregular use was that Help4Mood required a dedicated laptop. A 
laptop was necessary because of the computational requirements of the stable research 
prototype used for the trial. Dedicated laptops were set up by the research team to 
ensure optimal data protection, which is particularly important for stigmatised 
conditions such as MDD, and seamless communication with the specially developed 
actigraphy devices. Before undertaking a substantive trial, an app version of 
Help4Mood for tablet computers should be developed that requires fewer 
computational resources while maintaining user privacy.   
Future versions of Help4Mood should also allow greater flexibility in accessing 
components and planning sessions. The Virtual Agent, which is currently designed to 
behave like a professional therapist, needs to be extended with an additional, warmer, 
more expressive persona. 
The recruitment rate was lower than we have found in our previous trials of ehealth 
interventions21 but comparable to that for primary care trials of complex depression 
interventions in the UK.22 The commonest reason for exclusion of potential 
participants prior to enrolment was a BDI-2 score outside the prescribed range. We 
did not identify any reason for low recruitment in Spain which should influence the 
results.    
This illustrates the difficulty in undertaking pilot research in sensitive or higher-risk 
conditions, since clinicians may be reluctant to recommend an unproven addition to 
conventional treatment, and patients may be reluctant to try innovations that have not 
been strongly recommended by their clinicians.    
Nevertheless, the increased uptake and availability of mobile and online mood 
trackers – only a minority of which are scientifically validated - suggests that a 
 16 
system like Help4Mood can address an important patient need and should be 
investigated further. However, before embarking on a future trial, Help4Mood should 
be redesigned to include more components, permit more flexible sessions, and allow 
delivery via mobile devices.  
CONCLUSIONS 
Help4Mood, a novel virtual agent-based system to engage patients with depression in 
monitoring and treatment, was associated with potentially meaningful improvements 
in symptoms of depression among users who engaged regularly with it over the 
course of a four week trial. Virtual agent-supported treatments can potentially be a 
valuable part of caring for patients with depression, but further research is needed to 
establish the user groups most likely to benefit and the components most likely to be 
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Table 1 Functionality of the Help4Mood GUI  
Daily Mood Check CES-VAS-VA13 
Weekly Mood Check PHQ-9 242 
Negative Thoughts 
Module  
patients identify negative cognitions about a recent event and 
are challenged to consider a more positive interpretation. 
Items were taken from checklists of dysfunctional cognitions 
associated with depression,17, 25, 26 
Positive Thoughts 
Module   
patients identify positive cognitions about a recent event, 
based on positive reframing of items in the Negative 
Thoughts Module 
Sleep Questionnaire covers sleep duration, latency and disturbance 
Speech Measurements  three tasks including semiautomatic speech and a category 
fluency task 
Behavioural 
Activation   
based on tasks from lists of activities commonly used in 
behavioural activation. 
Relaxation Exercises  relaxation, grounding and visualisation techniques based on 
conventional psychological treatment, recorded for 




Table 2 Participant characteristics and baseline measures 
  
Treatment 
as Usual Help4Mood 
Sex    
 Female 8 10 
 Male 6 3 
Education   
 School 9 4 
 Higher 5 9 
Site    
 Romania 9 9 
 Scotland 4 3 
 Spain 1 1 
Current medication   
 No 6 8 
 Yes 8 5 
Age    
 Mean (SD) 42 (10.4) 35.3 (12.1) 
Baseline measures   
BDI-2  21.8 (6.8) 19.6 (8.1) 
QIDS-SR16 17.7 (6.2) 16.9 (7.2) 
DAS_SF2  24.5 (4.2) 20.1 (5.4) 
EQ-5D utility1 0.76 (0.19) 0.72 (0.21) 
EQ-5D - VAS 62.6 (17) 73.2 (19.2) 
 
BDI: Beck Depression Inventory, QIDS-SR: Quick Inventory of Depressive 
Symptoms- Self Report; DAS-SF: Dysfunctional Attitudes Scale Short Form; EQ-5D: 
EuroQol 5D 5Level; VAS Visual Analog Scale 
1 Utilities calculated using appropriate national tariffs. 
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Table 3, Mean changes from baseline of measures of depressive symptoms and 
cognitions and health related quality of life 
  Usual Care Help4Mood Difference 
  Mean SD change1 Mean SD change1   
BDI-22 17.6 6.8 -4.2 13.9 8.1 -5.7 -1.5 
QIDS-SR162 14.7 6.2 -3 14.2 7.2 -2.7 0.3 
DAS-SF22 23.5 4.2 -1 18.1 5.4 -2 -1 
EQ-5D Utility3 0.89 0.19 0.13 0.76 0.21 0.04 -0.09 
EQ-5D VAS3 79.9 17 17.3 75.2 19.2 2 -15.3 
 
BDI: Beck Depression Inventory, QIDS-SR: Quick Inventory of Depressive 
Symptoms- Self Report; DAS-SF: Dysfunctional Attitudes Scale Short Form; EQ-5D: 
EuroQol 5D 5Level; VAS Visual Analog Scale 
1change from baseline values listed in Table 2 
2For BDI, QIDS-SR and DAS-SF, lower values indicate better health 





Supplementary File 1 
Table showing number, type and duration of Help4Mood sessions by participant; 
 Individual sessions  Summary of sessions 
Patient1 







1 2 0 0 2 34 17 
2 4 0 8 12 189 13 
3 2 4 1 7 92 7 
4 6 8 9 23 369 11 
5 0 1 1 2 26 13 
6 9 6 4 19 150 9 
7 2 3 1 6 43 5 
8 6 2 3 11 195 16 
9 5 6 4 15 225 11 
10 4 2 4 10 118 8 
11 7 4 2 13 176 13 
12 2 1 4 7 106 19 
       
Total 49 37 41 127 1723   
 
 
                                                 
1 One participant not included because of technical failure resulting in loss of system log 
 
 
 
